Patient Derived Xenograft/PDX Models Market

Market Leader - Patient Derived Xenograft/PDX Models Market

The global PDX models market is projected to reach USD 167.6 Million by 2022 from USD 77.4 Million in 2017, at a CAGR of 16.7%. PDX models cater to a diverse group of end users, namely, pharmaceutical & biotechnology companies, contract research organizations (CROs), and academic & research institutions.

Pharmaceutical & Biotechnology companies are under immense pressure to accelerate drug development in the oncology arena. According to the International Federation of Pharmaceutical Manufacturers & Associations key facts 2017, the research-based pharmaceutical industry currently spends over USD 149.8 Billion on R&D activities per year. Government bodies across the globe are investing heavily in research activities for advancements in the field of cancer. PDX models are extensively used by pharmaceutical and biotechnology companies in oncology research as these models recapitulate various aspects of genesis, progression, and clinical course of human cancers. PDX models are established by the transplantation of a fresh human tumor specimen from a cancer patient directly into a mouse or rat. Thus, these models provide a near accurate assessment of human tumor biology, identification of therapeutic targets, preclinical screening, and evaluation of drugs for various cancers.

CROs provide services to pharmaceutical and biopharmaceutical companies, research institutions, and universities, among others. These services include biopharmaceutical development, biologic assay development, preclinical research, clinical research, and clinical trial support. Many pharmaceutical companies outsource either part of the project or the whole project to CROs to focus on their core competencies and reduce time to launch new drugs. The growing number of research studies on various human diseases like cancer is expected to increase the usage of PDX models for performing clinical trials.

Academic institutions, as well as various dedicated public and private research institutions, are extensively involved in biomedical and medical research using PDX models. With the growth in the number of cancer research studies, the demand for PDX models is expected to increase.

Crown Bioscience Inc. is one of the strongest players in the PDX models market, having facilities across the US, the UK, China, and Taiwan. The company focuses on discovering new oncology drugs and is continuously expanding its PDX models bank to recapitulate the diversity and complexity of human cancer biology in the laboratory. The company is strongly engaged in organic and inorganic growth strategies like expansions and agreements/partnerships/collaborations, respectively. The company did more than five expansions and about five agreements/partnerships/collaborations in the last three years. For instance, in 2017, Crown Bioscience entered into an agreement with The Jackson Laboratory to develop innovative research models and preclinical services for the global biomedical research community.

Champions Oncology is also one of the leading players in the PDX models market and operates in the field of oncology research, both through translational oncology and personalized oncology platforms. The company has a strong tumor bank. Champions Oncology has a strong focus on the development of its TumorGraft Technology Platform. The firm is working to expand its TumorBank through various research collaborations and relationships with hospitals and academic institutions. In addition, Champions has also grown their TumorBank through their POS business. Champions Oncology has been continuously engaged in making agreements with various pharmaceutical companies. For instance, in 2017, the company signed a contract with a pharmaceutical company (name not disclosed) for various studies on immune oncology drugs utilizing its patient-derived xenograft (PDX) models.

The other players of the PDX models market include WuXi AppTec (China), The Jackson Laboratory (US), ONCODESIGN (France), and Charles River Laboratories International, Inc. (US).

Related Reports:

Patient Derived Xenograft/PDX Models Market by Type (Mouse & Rat), Tumor Type (Gastrointestinal, Gynecological, Respiratory), Application (Pre-Clinical Drug Development & Biomarker Analysis), End User (Pharma & Biotech, CRO) - Global Forecast to 2022

Contact:
Mr. Rohan
MarketsandMarkets™
701 Pike Street,
Suite 2175, Seattle,
WA 98101, United States
1-888-600-6441
Email: sales@marketsandmarkets.com

Report Code
BT 5576
Published ON
Sep, 2017
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Patient Derived Xenograft/PDX Models Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
REQUEST A FREE WORKSHOP
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
ONLINE CHAT
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
© MarketsandMarkets Research Private Ltd. All rights reserved